.

Deeper Knowledge, Faster

  • Predict branded drug patent expiration
  • Uncover prior art in expired and abandoned patents
  • Set up watchlists for daily email updates

► See Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Harvard Business School
QuintilesIMS
Fish and Richardson
Chinese Patent Office
AstraZeneca
Citi
Mallinckrodt
Fuji
Cantor Fitzgerald
Deloitte

Generated: June 24, 2017

DrugPatentWatch Database Preview

Details for Patent: 6,987,101

« Back to Dashboard

Which drugs does patent 6,987,101 protect, and when does it expire?


Patent 6,987,101 protects YAZ and is included in one NDA. There has been one Paragraph IV challenge on Yaz.

This patent has three patent family members in three countries.

This patent has expired prematurely due to non-payment of maintenance fees. See details below.

Summary for Patent: 6,987,101

Title:Therapeutic gestagens for the treatment of premenstrual dysphoric disorder
Abstract:A method for treating premenstrual dysphoric disorder comprises administering a therapeutically effective amount of a gestagen. Optionally, a natural or synthetic estrogen is also administered. In one embodiment, the gestagen and optional estrogen are administered during the luteal phase of the female menstrual cycle, preferably from day 10 to day 28.
Inventor(s): Nashed; Norman (Munchen, DE)
Assignee: Schering Aktiengesellschaft (Berlin, DE)
Application Number:09/619,493
Patent Claim Types:
see list of patent claims
Use; Delivery;

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use
Bayer Hlthcare
YAZ
drospirenone; ethinyl estradiol
TABLET;ORAL021676-001Mar 16, 2006ABRXYesYes6,987,101► Subscribe TREATMENT OF SYMPTOMS OF PREMENSTRUAL DYSPHORIC DISORDER
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Foreign Priority and PCT Information for Patent: 6,987,101

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany196 54 609Dec 20, 1996

International Patent Family for Patent: 6,987,101

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
World Intellectual Property Organization (WIPO)9827929► Subscribe
Germany19654609► Subscribe
Australia5981098► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Merck
McKesson
Citi
Boehringer Ingelheim
Healthtrust
McKinsey
Argus Health
Johnson and Johnson
Cerilliant
Novartis

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot